Skip to main content

Facilitating Collaborations to Develop Combination Investigational Cancer Therapies Workshop Summary (2012) / Chapter Skim
Currently Skimming:

Appendix B: Workshop Agenda
Pages 91-96

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 91...
... Appendix B Workshop Agenda June 13 and 14, 2011 The Keck Center of the National Academies, Room 100 500 Fifth Street, NW Washington, DC 20001 June 13, 2011 7:30 am Breakfast and Registration 8:00 am Welcome from the IOM National Cancer Policy Forum John Mendelsohn, MD Anderson Cancer Center, and Chair, National Cancer Policy Forum 8:05 am Session 1: Workshop Introduction Moderator: John Hohneker, Novartis Pharmaceuticals, Workshop Planning Chair Rationale for Developing Combination Targeted Cancer Therapies • effrey Engelman, Massachusetts General Hospital J Application of Genomic Tools to Assist in Combination Therapy Development • Michael Barrett, TGen Patient Advocate Perspective • Jane Perlmutter, Gemini Group Panel Discussion (30 minutes)
Read the entire page →
From page 92...
... 92 COLLABORATIONS TO DEVELOP COMBINATION CANCER THERAPIES 9:35 am Session 2: Scientific Challenges and Opportunities: Preclinical Issues in Codevelopment Moderator: James Zwiebel, National Cancer Institute Perspectives from the National Cancer Institute • James Doroshow, National Cancer Institute Perspectives from Academia • David Stern, Yale University • Carl June, University of Pennsylvania Perspectives from Industry • Kurt Bachman, GlaxoSmithKline Panel Discussion (60 minutes) Includes speakers and • Haleh Saber, Food and Drug Administration • Robert Iannone, Merck • Michael Caligiuri, OSU Comprehensive Cancer Center 12:00 pm Lunch 1:00 pm Session 3: Scientific Challenges and Opportunities: Clinical Issues in Codevelopment Moderator: Roy Herbst, Yale Cancer Center Perspectives from the National Cancer Institute • Helen Chen, National Cancer Institute Perspectives from Academia • atricia LoRusso, Barbara Ann Karmanos Cancer P Institute Perspectives from Industry • Stuart Lutzker, Genentech Perspectives on Trial Design and Statistical Issues • Donald Berry, MD Anderson Cancer Center • Larry Rubinstein, National Cancer Institute
Read the entire page →
From page 93...
... Includes speakers and • Robert Temple, CDER, Food and Drug Administration • Ellen Sigal, Friends of Cancer Research 5:30 pm Adjourn, Day 1 June 14, 2011 7:30 am Breakfast and Registration 8:00 am Welcoming Remarks John Hohneker, Novartis Pharmaceuticals, Workshop Planning Chair 8:10 am Session 5: Codevelopment in Vaccines, Biologics, and Other Therapeutic Areas Moderator: Renzo Canetta, Bristol-Myers Squibb Experiences from HIV Drug and Vaccine Development • arl Dieffenbach, National Institute of Allergy and C Infectious Diseases • ary Nabel, National Institute of Allergy and Infectious G Diseases
Read the entire page →
From page 94...
... Industry perspective • ydia McNally, Novartis L Research institution/technology transfer perspective • esley Blakeslee, Johns Hopkins W National Cancer Institute perspective • ason Cristofaro, National Cancer Institute J • herry Ansher, National Cancer Institute S 11:55 am Break: Please pick up boxed lunch and return to workshop 12:15 pm Session 6 (Continued)
Read the entire page →
From page 95...
... 95 APPENDIX B Practical Examples and Possible Models of Collaboration Collaborations to Develop Drugs Targeting PI3K • Lewis Cantley, Beth Israel Hospital/Harvard BATTLE 1 and 2 Trials • Roy Herbst, Yale Cancer Center I-SPY 2 TRIAL • David Wholley, Biomarkers Consortium Panel Discussion (45 minutes) Includes speakers and • assiliki Papadimitrakopoulou, MD Anderson Cancer V Center 1:50 pm Closing Comments/Wrap-Up John Hohneker, Novartis Pharmaceuticals 2:00 pm Adjourn
Read the entire page →

Key Terms

  • novartis pharmaceuticals
  • john hohneker
  • institute perspective
  • includes speakers
  • workshop planning

  • national cancer
  • industry perspective
  • planning chair
  • transfer perspective
  • boxed lunch

  • please pick
  • vaccine development
  • welcoming remarks
  • renzo canetta
  • infectious diseases

  • remarks john
  • hiv drug


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.